Community

Share Your Story, Inspire Hope

Your journey can be a beacon of hope and a source of strength for others in our community. Together, we can build a stronger, more supportive community. Your story matters, and it deserves to be heard. Fill in this form to be featured.

Latest News

Italy Approves Reimbursement for New Treatments, Offering Hope to Rare Disease Patients

Italy's AIFA has approved the reimbursement for Pombiliti and Oploda, offering new hope for patients with Pompe disease. These treatments aim to improve the quality of life and manage symptoms of the condition, providing financial relief to those affected. This approval is a significant step forward in accessible care for Pompe disease patients.

Managing a Lingering Stomach Bug During the New Year

Managing a lingering stomach bug during the holiday season can be challenging, especially for those with Pompe disease. This article offers practical tips and strategies to help cope with digestive issues, maintain nutrition, and stay hydrated while dealing with gastrointestinal symptoms. It emphasises the importance of communicating with healthcare providers and adapting holiday plans to ensure comfort and health.

Pompe Disease Market Expected to Grow Significantly by 2034, Says DelveInsight Report

The Pompe disease market is expected to grow significantly from 2024 to 2034, driven by increasing diagnosis rates, advancements in treatment options, and rising demand for effective therapies. DelveInsight's analysis highlights key drivers, challenges, and potential market opportunities for Pompe disease treatments.

Community

We want to hear your story!

Fill in the form to share your experiences and any challenges you’ve faced living with your condition, for a chance to be featured in one of our weekly newsletters!

Latest News

Community

We want to hear your story!

Fill in the form to share your experiences and any challenges you’ve faced living with your condition, for a chance to be featured in one of our weekly newsletters!

Latest News

Genetic Panel Helps Distinguish Between Pompe Disease and Muscular Dystrophy, Study Finds

A new genetic panel can help differentiate between Pompe disease and muscular dystrophy, according to a recent study. The panel identifies specific genetic mutations, aiding in accurate diagnosis and treatment plans for patients with these conditions. This advancement is crucial for managing and treating Pompe disease effectively.

ERT Shows Promise for Rare Genetic Disorder in Patients

The study focuses on the long-term outcomes of enzyme replacement therapy (ERT) in patients with pompe disease, highlighting improvements in muscle strength, respiratory function, and overall quality of life. It emphasizes the importance of early treatment initiation and consistent therapy to manage the disease effectively.

Therapies and Diagnostic Approaches for Rare Neurological Disorders in Patients

The article discusses the diagnosis and management of Pompe disease, focusing on the role of enzyme replacement therapy (ERT) in improving muscle function and quality of life. It highlights the importance of early diagnosis and tailored treatment strategies for optimal outcomes in patients with Pompe disease.

Community

We want to hear your story!

Fill in the form to share your experiences and any challenges you’ve faced living with your condition, for a chance to be featured in one of our weekly newsletters!

Latest News

New Drug Shows Promise in Overcoming Limitations of Older Treatments for Rare Genetic Disorder

Pombiliti and opfolda, new treatments for pompe disease, are showing promise in overcoming the limitations of older enzyme replacement therapies (ERTs), offering potential improvements in patient outcomes and quality of life. These newer treatments aim to address the challenges faced by patients with pompe disease.

New Enzyme Replacement Therapy Shows Promise in Treating Rare Genetic Disorder

Researchers studied the safety and efficacy of a new enzyme replacement therapy for pompe disease, finding it to be well-tolerated and effective in improving muscle function and reducing glycogen levels in patients. The study highlights potential benefits of this treatment for managing the disease.

Trumps Presidency Return: Boom or Bust for Biopharmaceutical Deal Activity?

Researchers studied the safety and efficacy of a new enzyme replacement therapy for pompe disease, finding it to be well-tolerated and effective in improving muscle function and reducing glycogen levels in patients. The study highlights potential benefits of this treatment for managing the disease.

Community

We want to hear your story!

Fill in the form to share your experiences and any challenges you’ve faced living with your condition, for a chance to be featured in one of our weekly newsletters!

Latest News

Three Genes Identified as Potential Biomarkers for Disease Progression in Patients

Researchers have identified three genes that could serve as biomarkers to track the progression of Pompe disease. These genes may help predict how the disease will advance in patients, allowing for more personalized and effective treatment plans. This discovery could improve the management and care of individuals with Pompe disease.

Third Ear Tube Surgery for Son in Quest to Bring Relief

The article discusses a personal experience of a child with Pompe disease undergoing multiple ear tube placement surgeries due to recurring ear infections, a common issue in children with the condition. It highlights the challenges and emotional toll on families managing such health issues.

New Treatment Shows Promise for Rare Genetic Disorder in Patients

Researchers explored the effectiveness of enzyme replacement therapy (ERT) in patients with Pompe disease, highlighting its benefits in improving muscle function and overall health. The study discusses the importance of early diagnosis and treatment initiation to maximize therapeutic outcomes for those with Pompe disease.

Community

We want to hear your story!

Fill in the form to share your experiences and any challenges you’ve faced living with your condition, for a chance to be featured in one of our weekly newsletters!

In the News

Discovering Key Genes in Pompe Disease Through Machine Learning

This study explores immune cell infiltration in infantile-onset Pompe disease using bioinformatics and machine learning. Key genes GPNMB, CALML6, and TRIM7 were identified, linked to immune responses. Findings suggest potential biomarkers and therapeutic targets, offering hope for improved diagnosis and treatment, though further research is needed for validation.

Feeding Therapy Offers Hope for Children with Pompe Disease

Keara Engle explores feeding therapy for her son, Cayden, who has Pompe disease and uses a G-tube. She hopes therapy will help him eat orally. Cayden's new speech therapist suggested a nearby facility offering feeding therapy, and Keara plans to schedule an appointment soon.

Pompe Disease Diagnosed in Over 700 Patients Using Two-Step Process

A two-step process involving biochemical and genetic testing has successfully diagnosed over 700 individuals with Pompe disease from 57 countries. This approach, which screened over 30,000 suspected cases, highlights the importance of early diagnosis for effective treatment, offering hope and support to affected families worldwide.

Avalglucosidase Alfa Home Infusion: Safe and Effective for Pompe Patients

Avalglucosidase alfa home infusions for Pompe disease patients were safe and effective in clinical trials. Seventeen participants received 419 infusions at home, with adverse events comparable to clinic settings. This approach reduces treatment burden, enhancing quality of life for patients and caregivers.

Community

We want to hear your story!

Fill in the form to share your experiences and any challenges you’ve faced living with your condition, for a chance to be featured in one of our weekly newsletters!

In the News

Navigating work and school with Pompe disease

Navigating work and school with Pompe disease involves managing challenges like mobility issues and fatigue. Support is available through aides, workplace adaptations, and healthcare professionals. Personal stories highlight the importance of accommodations and legal protections, fostering a supportive environment for those affected by Pompe disease.

An important message to the parents of a newly diagnosed child

Keara Engle shares her journey as a parent of a child with Pompe disease, offering support to others facing similar challenges. She emphasises the initial loneliness and fear but highlights resilience and adaptation over time. Her message is one of hope, encouraging parents to embrace their unique journey.

The European reference network for metabolic diseases (MetabERN) clinical pathway recommendations for Pompe disease

The European Reference Network for Metabolic Diseases (MetabERN) has developed clinical pathway recommendations for Pompe disease. These guidelines aim to standardise care across Europe, focusing on diagnosis, treatment, and follow-up. The recommendations are based on a systematic literature review and expert consensus, ensuring comprehensive and accessible care.

Phase 1b study of Pompe disease treatment seeks adults

Aro Biotherapeutics is recruiting adults with late-onset Pompe disease for a Phase 1b trial of ABX1100, a new treatment aiming to reduce glycogen production. This approach offers hope beyond enzyme replacement therapy. The trial, starting in Canada, seeks to improve safety and effectiveness for this underserved community.

Community

We want to hear your story!

Fill in the form to share your experiences and any challenges you’ve faced living with your condition, for a chance to be featured in one of our weekly newsletters!

In the News

Jefferson City Family Faces Uncertainty Over Son's Pompe Drug Coverage

The Dudenhoeffer family in Jefferson City faces a challenging situation regarding their son's costly Pompe disease medication, which may not be covered under a new insurance plan. Despite efforts by the city to balance budgets, the family is concerned about potential loss of coverage. Meghan Dudenhoeffer is actively seeking support and solutions to address this issue.

Aro Biotherapeutics Begins Phase 1b Trial for Pompe Disease Treatment

Aro Biotherapeutics is advancing the field with ABX1100, a novel therapy for late-onset Pompe disease. This Phase 1b trial aims to target muscle glycogen accumulation using siRNA technology. Following promising results from Phase 1a, the company is now enrolling patients for the next stage of the trial, which may represent a significant advancement beyond traditional enzyme replacement therapy.

Extracellular Vesicle Biomarkers in Pompe Disease Research

In a recent study, researchers investigated exosomes in a Pompe disease mouse model, uncovering potential biomarkers for disease monitoring. By analyzing miRNA and protein levels in urine and blood samples, they identified notable differences that may provide new insights into therapeutic approaches. This research offers a valuable glimpse into the microscopic landscape of Pompe disease.

Social Media Enhances Rare Disease Clinical Trial Recruitment

Social media is transforming recruitment for rare disease clinical trials, according to the CEO of Andarix. By effectively targeting motivated patients, response rates have increased to 40%. However, it is essential to be vigilant about misinformation. Patient registries such as NORD and CoRDS also play a critical role in this process. Thus, social media serves as both a valuable tool and a potential source of challenges in rare disease research.

In the News

Navigating Palliative Care Decisions for Children with Pompe Disease

The article explores the emotional journey of families making palliative care decisions for children with Pompe disease. Through a qualitative case study, it highlights the supportive role of healthcare teams in Brazil, emphasising empathy and understanding in navigating these challenging choices, fostering hope and community support.

Early Diagnosis Key in Pompe Disease Treatment Success

Early diagnosis and treatment of late-onset Pompe disease significantly enhance the effectiveness of enzyme replacement therapy (ERT). This case report of a 38-year-old Iranian woman highlights the challenges of late diagnosis, showing limited improvement in muscle strength and respiratory function despite ERT, underscoring the importance of timely intervention.

Carbon Spectroscopy Reveals Glycogen Patterns in Pompe Disease

Carbon MR spectroscopy at 3 Tesla effectively measures muscle glycogen in late onset Pompe patients. The study found increased glycogen in the Semitendinosus muscle, but no correlation with muscle function or treatment. This non-invasive method offers hope for better monitoring in clinical trials, supporting patient care advancements.

Cipaglucosidase Alfa/Miglustat Therapy Enhances Pompe Disease Treatment Outcomes

Cipaglucosidase alfa/miglustat therapy significantly improves outcomes for late-onset Pompe disease patients, enhancing motor and lung function, muscle strength, and quality of life. The FDA-approved treatment, based on the PROPEL study, offers hope and improved efficacy for those previously on enzyme replacement therapy.

Digital Innovation in the NHS

Digital Patient Passports to Revolutionise NHS Healthcare

Wes Streeting, the health secretary, has unveiled an ambitious plan to revolutionise healthcare in the UK by introducing patient passports, which will digitally store all NHS medical records in one accessible location. This transformative initiative aims to enhance patient care by allowing swift access to health data for GPs, hospitals, and ambulance services, thereby reducing repeat tests and medication errors. The digital data bill will standardise information systems across the NHS, creating a unified patient record on the NHS app. 

Despite the potential benefits, concerns about privacy and data security have been raised. Critics, including medConfidential, warn that the centralised database could become a target for hackers and misuse by unauthorised personnel. Public scepticism is evident, with a significant portion of the population expressing distrust in the NHS's ability to keep data secure. 

Streeting, however, remains optimistic, emphasising the collaboration with tech and pharma companies to develop new treatments and ensure the NHS benefits from cutting-edge advancements. He assures that patient data will be protected and anonymised, addressing fears of "big brother" oversight. The government is also focusing on shifting healthcare from hospitals to community-based centres and prioritising prevention over treatment, with plans to distribute wearable tech for health monitoring. 

This bold vision for the NHS seeks to harness the power of digital innovation to improve healthcare delivery, but it must navigate the delicate balance between technological advancement and patient privacy.

Community Voices

Have Your Say